Alliances
Neurimmune today announced the achievement of a key preclinical milestone in the ongoing collaboration with Ono Pharmaceutical Co., Ltd. In November 2017, the parties entered into a collaboration focused on the development of human-derived antibodies against a novel therapeutic target for neurodegenerative diseases.
BeiGene to build late-stage clinical and commercial production capacity for cancer monoclonal antibodies with GE Healthcare’s KUBio, the prefabricated biopharma facility based on single-use technologies
Supported by two clusters with a focus on digital and medical activities and backed by industry groups and over 45 innovative companies, the Hu-PreciMED project will gear the French precision medicine industry towards discovering new diagnostic approaches and novel therapeutic treatments more rapidly
Joint R&D work aims at microbial strain development for the production of high-value chemicals including bioplastics
Option-based Collaboration to Develop Two CAR T-Cell Product Candidates Using Fate’s Proprietary iPSC Product Platform
The US-based aviation maintenance, repair and overhaul (MRO) and manufacturing organisation will adopt Q-Pulse FAIR to help with contracts relating to Airframe OEM’s
Medtronic CEO Omar Ishrak Commits to Continue Accelerating Diversity, Inclusion and Gender Equality
CRISPR Therapeutics and ViaCyte are collaborating to discover, develop and commercialize a gene-edited allogeneic stem cell therapy or therapies for diabetes.
Without a doubt China has become one of the most important markets for pharma companies, given the vast patient population and the rising cancer rates. And it seems that western pharmaceutical companies are making greater inroads there.
Advanced Cell Therapy Shanghai Summit October 29-31, 2018
PRESS RELEASES